Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 24, 2024 - Issue 7: Biosimilars 2024
Submit an article Journal homepage
120
Views
0
CrossRef citations to date
0
Altmetric
Review

Systematic review: effectiveness and safety of switching between originator infliximab and biosimilar infliximab in patients with inflammatory bowel disease

Gary R. Lichtensteina Department of Internal Medicine, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, PA, USACorrespondence[email protected]
View further author information
,
Arif Soonasrab Global Medical Affairs, Pfizer Inc., Collegeville, PA, USAView further author information
,
Mark Latymerc Global Medical Affairs, Pfizer Ltd., Sandwich, UKView further author information
,
Sheena Singhd Value and Access, Curo, Envision Pharma Group, London, UKView further author information
&
Brian G. Feagane Robarts Research Institute, Western University, London, ON, CanadaView further author information
Pages 691-708 | Received 08 Apr 2024, Accepted 05 Jul 2024, Published online: 18 Jul 2024

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

Order Reprints Request Permissions

For more information please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.